Bacteremia occurs when bacteria are present in the bloodstream, which is normally a sterile environment. As these bacteria multiply, a potentially life-threatening infection called sepsis can develop. These conditions arise from bacteria originating elsewhere in the body, including the lungs, abdomen, and urinary tract. Our bacteremia studies allow for in vivo screening of antimicrobial activity to rapidly identify the most promising therapies.

Procedure
We have established a bacteremia model in mice (validation in rats is available upon request) in which animals are challenged with a pathogen via intravenous (IV) injection in the lateral tail vein. Animals may be administered test article via oral gavage (PO) or subcutaneous (SC), intravenous (IV), or intraperitoneal (IP) injection. Each study parameter (animal strain, pathogen, comparator(s), and dosing schedule) can be customized to meet client needs.

Endpoints for this study include mortality tracking and CFU load in harvested organs and/or blood. Pharmacokinetic profiling, blood chemistry, additional tissue harvests, and histology are available upon request.

Sample Data

Pathogens
TransPharm has validated a bacteremia model using the following pathogens:

• Enterococcus faecalis
  • ATCC 700802
• Pseudomonas aeruginosa 
  • ATCC 13073
• Staphylococcus aureus
  • ATCC 25904
  • USA300
• Streptococcus pneumoniae 
  • ATCC 700674
• Streptococcus pyogenes
  • SP1-1

Additional validations are available upon request.